Phase II trial of CI-958 in recurrent platinum-refractory ovarian carcinoma. A Gynecologic Oncology Group Study.
The objectives of this study were twofold: (1) to estimate the anti-tumor efficacy of CI-958 in patients with measurable platinum-resistant ovarian cancer; (2) to determine the nature and degree of toxicity of CI-958 in these patients. Patients received CI-958 560 mg/m(2) intravenously every 3 weeks and tumor measurements were performed every one to two cycles. In 25 cases with recurrent platinum-resistant disease, there was one partial response (PR) and six patients had stable disease (SD). CI-958 has minimal activity in platinum-resistant ovarian cancer at the dose and schedule tested.